雷珠单抗与阿柏西普治疗新生血管性年龄相关性黄斑变性伴视网膜色素上皮脱离:一项观察性研究数据
该研究为一项前瞻性设计并实施的临床审计的回顾性分析,纳入92/233只未治疗过的新生血管性年龄相关性黄斑变性伴视网膜色素上皮脱离(RPED)眼,比较阿柏西普与雷珠单抗治疗6个月后RPED尺寸和视力的变化。结果显示两组在RPED最大高度、直径和视力变化上均无显著组间差异,约30%的眼在6个月时RPED完全消退。
要点
- 两组6个月时RPED最大高度、直径及视力变化的校正均值差异均无统计学显著性。
- 注射频率是唯一影响两组RPED高度和视力变化的临床变量。
- 每组约30%的眼在6个月时RPED完全消退。
核心结论
- 新生血管性年龄相关性黄斑变性伴RPED眼接受玻璃体腔内抗血管内皮生长因子注射6个月后,功能和anatomical均有显著反应。
- 雷珠单抗与阿柏西普在anatomical反应或视力变化上无显著差异。
- 作者认为,更大规模、前瞻性设计、随访更长的随机研究可能发现本研究未能检出的两药差异。
研究设计与样本
- 研究为对一项前瞻性设计并实施的临床审计数据的回顾性分析。
- 分析纳入92/233只未治疗过的新生血管性年龄相关性黄斑变性伴RPED眼,治疗为阿柏西普或雷珠单抗,观察6个月。
- 分析内容包括RPED尺寸变化和视力。
主要发现
- 6个月时RPED最大高度(P=0.195)、直径(P=0.522)和视力(P=0.836)的校正均值变化均无显著组间差异。
- 注射频率是唯一影响两组RPED高度(P=0.050)和视力变化(P=0.004)的临床变量。
- 每组约30%的眼在6个月时RPED完全消退。
局限性
- 原文指出,需要更大规模、前瞻性设计、随访更长的随机研究,才可能发现本研究未能检出的两药差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the effect of intravitreal ranibizumab and aflibercept on retinal pigment epithelial detachment (RPED) in patients with neovascular age-related macular degeneration. METHODS: This was a retrospective analysis of data from a prospectively designed and implemented clinical audit. Analysis included change in RPED dimensions and visual acuity in 92/233 treatment-naive eyes with neovascular age-related macular degeneration and RPED 6 months after treatment with either aflibercept or ranibizumab. RESULTS: There was no significant between-group difference in the adjusted mean change for maximum RPED height (P = 0.195), diameter (P = 0.522) or visual acuity (P = 0.836) at 6 months. Injection frequency was the only clinical variable that affected RPED height (P = 0.050) and visual acuity change for both treatment groups (P = 0.004). Around 30% of eyes in each group had complete resolution of RPED at 6 months. CONCLUSION: Eyes with neovascular age-related macular degeneration and RPED showed significant functional and anatomical responses after 6 months of intravitreal anti-vascular endothelial growth factor injections. However, we found no significant difference in anatomical response or change in visual acuity between eyes treated with ranibizumab compared with aflibercept. Larger, prospectively designed, randomized studies with longer term follow-up may identify a difference between the two drugs that we did not detect.
引用
- Vaze A, Nguyen V, Daien V, et al. RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Data from an Observational Study. Retina. 2018. PMID: 28820848. doi:10.1097/IAE.0000000000001815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。